What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden
ARTICLE;
CLINICAL PRACTICE;
COST CONTROL;
DRUG COST;
DRUG NOMENCLATURE;
HEALTH CARE COST;
HEALTH CARE POLICY;
HEALTH INSURANCE;
ILLNESS BEHAVIOR;
MEDICAID;
PATIENT ATTITUDE;
PHARMACY;
PHYSICAL DISEASE;
PRESCRIPTION;
PRIORITY JOURNAL;
SWEDEN;
CHOICE BEHAVIOR;
COMMUNITY PHARMACY SERVICES;
DRUG UTILIZATION;
DRUGS, GENERIC;
HUMANS;
LEGISLATION, DRUG;
PATIENTS;
PHYSICIAN'S PRACTICE PATTERNS;
PHYSICIANS;
PRESCRIPTION FEES;
PRESCRIPTIONS, DRUG;
SWEDEN;
How do practitioners evaluate the newly introduced system of substituting prescriptions?
Rubak SL, Andersen ML, Mainz J, Olesgaard P, Lauritzen T. How do practitioners evaluate the newly introduced system of substituting prescriptions? Ugeskr Laeger 2000; 162: 6070-6073.
How do patients evaluate the newly introduced system of substituting prescriptions?
Andersen ML, Laursen K, Schaumann M, et al. How do patients evaluate the newly introduced system of substituting prescriptions? Ugeskr Laeger 2000; 162: 6066-6069.
Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia
McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Safe 2001; 10: 295-300.
What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?
Schneeweiss S, Schoffski O, Selke GW. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 1998; 44: 253-260.
Providing incentives to control health care costs and remain competitive in the market-place: A pilot study
Tootelian DH, Royer J, Johnson RC. Providing incentives to control health care costs and remain competitive in the market-place: a pilot study. Health Mark Q 1997; 15: 87-99.
Potential savings from increased use of generic drugs in the elderly: What the experience of Medicaid and other insurance programs means for a Medicare drug benefit
Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Safe 2004; 13: 207-214.
